Michael Kalos BS, PhD

Dr Michael Kalos is a graduate of the University of Minnesota Medical School, where he received his PhD from the department of Microbiology with an emphasis in Genetics. He completed postdoctoral fellowships at the Fred Hutchinson Cancer Research Center where he played an early role in the development of genetic approaches to redirect lymphocyte specificity.
In 1997, Dr Kalos joined Corixa Corporation, where he engaged in the pre-clinical immunological evaluation of novel cancer vaccines for prostate and lung cancer. In 2004, Dr Kalos was recruited to City of Hope where he established a GLP-level laboratory focused on the development of biomarker strategies to evaluate T-cell immunotherapies. In 2008,
Dr Kalos was recruited to the University of Pennsylvania School of Medicine where he established the Translational and Correlative Studies Laboratory, focused on development and implementation of an integrated biomarker infrastructure as part of the institution’s T-cell immunotherapy program. Data from his laboratory played an instrumental role in the clinical evaluation and development of the CTL019 program, and has led to a series of high-impact and field-leading publications.